These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10623362)

  • 1. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.
    Wisløff F; Gulbrandsen N; Nord E
    Pharmacoeconomics; 1999 Oct; 16(4):329-41. PubMed ID: 10623362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
    Gulbrandsen N; Wisløff F; Nord E; Lenhoff S; Hjorth M; Westin J;
    Eur J Haematol; 2001 May; 66(5):328-36. PubMed ID: 11422413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.
    Henon P; Donatini B; Eisenmann JC; Becker M; Beck-Wirth G
    Bone Marrow Transplant; 1995 Jul; 16(1):19-25. PubMed ID: 7581122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
    Nord E; Wisløff F; Hjorth M; Westin J
    Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
    Kim MY; Sposto R; Swaika A; Asano H; Alamgir A; Chanan-Khan A; Ailawadhi S
    Oncology; 2014; 87(4):224-31. PubMed ID: 25059308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
    Hjorth M; Lenhoff S; Turesson I; Westin J
    Lakartidningen; 2000 Oct; 97(41):4585-6, 4589-92. PubMed ID: 11107744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
    Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
    J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
    Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
    Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional chemotherapy in multiple myeloma.
    Westin J
    Pathol Biol (Paris); 1999 Feb; 47(2):169-71. PubMed ID: 10192883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
    Trippoli S; Messori A; Becagli P; Alterini R; Tendi E
    Oncol Rep; 1998; 5(6):1475-82. PubMed ID: 9769391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.